Panel Discussion: To What Degree Does Neuroplasticity Underpin Psychedelics Efficacy?

• Examining the evidence linking psychedelic induced synaptic and dendritic remodeling with changes in mood, cognition and emotional processing
• Exploring whether neuroplasticity is a mechanistic driver of efficacy or a downstream accompaniment to broader network level changes
• Comparing plasticity linked biomarkers, such as EEG signatures, sleep architecture shifts and neurotrophic factor changes, to determine which most reliably map onto clinical response
• Debating how much neuroplasticity is necessary, sufficient or even predictive for therapeutic benefit across different psychedelic and non psychedelic compounds
• Considering maladaptive behaviors underpinned by neuroplasticity in the brain
• How might we treat “neuroplastogens” differently: as a separate class

Speakers:

Magali Haas

Chief Medical Officer

Psilera

Umed Boltaev

Research Director, Neuroscience

Helus Pharma

Matt Harlin

Senior Director, Discovery Research

Otsuka America Pharmaceutical, Inc

Scott thompson

Professor, Department of Psychiatry

University of Colorado Anschutz Medical Campus